# Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis

> **NCT02728934** · — · COMPLETED · sponsor: **Janssen Scientific Affairs, LLC** · enrollment: 1279 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **BIOLOGICAL:** Golimumab Intravenous (IV)
- **BIOLOGICAL:** Infliximab
- **BIOLOGICAL:** Biosimilar Infliximab

## Key facts

- **NCT ID:** NCT02728934
- **Lead sponsor:** Janssen Scientific Affairs, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-25
- **Primary completion:** 2020-01-31
- **Final completion:** 2020-01-31
- **Target enrollment:** 1279 (ACTUAL)
- **Last updated:** 2020-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02728934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02728934, "Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02728934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*